載入...

Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas

INTRODUCTION: Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD‐L1 DAKO 22C3) for urothelial carcinoma (UC). In this study, we further characterize the clinicopathologic and genomic features of UC that are programmed death‐ligand 1 (PD‐L1) positive. MATERIALS AND M...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Huang, Richard S.P., Haberberger, James, Harries, Lukas, Severson, Eric, Duncan, Daniel L., Ferguson, N. Lynn, Hemmerich, Amanda, Edgerly, Claire, Murugesan, Karthikeyan, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Hiemenz, Matthew, Venstrom, Jeffrey, Elvin, Julia A., Creeden, James, Lin, Douglas I., Ross, Jeffrey S., Ramkissoon, Shakti H.
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2021
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100538/
https://ncbi.nlm.nih.gov/pubmed/33687775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13753
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!